The Dearth of Antibiotic Development

Explore the critical issue of antibiotic scarcity in this 44-minute conversation featuring experts Dr. Helen Boucher and Dr. Karen Bush. Delve into the reasons behind the declining antibiotic development pipeline, examine new initiatives aimed at revitalizing the antibiotic market, and discover strategies to boost antibiotic development. Learn about the challenges facing pharmaceutical companies, the potential of betalactamase inhibitors, and the impact of regulatory environments on drug development. Gain insights into the AMR Action Fund, nonprofit approaches, and proposed incentives to stimulate antibiotic research. Understand the complexities of clinical trials, patient recruitment issues, and the evolving landscape of antimicrobial resistance. Conclude with expert predictions and final thoughts on addressing this global health concern.

Introduction
How did we get here
Why is this happening
How can we tackle this
Betalactamase inhibitors
Potential for antagonism
AMR Action Fund
Thoughts on AMR Fund
Solutions
Predictions
FDA vs clinical trials
Lack of patients
Regulatory environment
Nonprofit
Small pipeline
Antibiotic incentives
Final thoughts